Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
Objectives:

To evaluate the safety and effectiveness of cell therapy using Precision Cell Immunotherapy to treat Advanced Gastric Cancer.

Eligibility:

Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Gastric Cancer.
Precision Cell Immunotherapy|Chemotherapy|Advanced Malignancies
DRUG: Chemotherapy|BIOLOGICAL: Precision Cells
Overall survival, 2 years|Progress-free survival, 2 years
Quality of life, 2 years
A total of 40 patients may be enrolled over a period of 1-2 years.